Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3125457
Max Phase: Preclinical
Molecular Formula: C21H25ClO6
Molecular Weight: 408.88
Molecule Type: Small molecule
Associated Items:
ID: ALA3125457
Max Phase: Preclinical
Molecular Formula: C21H25ClO6
Molecular Weight: 408.88
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: [2H]C([2H])(c1ccc(OCC)cc1)c1cc([C@]2([2H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)ccc1Cl
Standard InChI: InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1/i9D2,21D
Standard InChI Key: JVHXJTBJCFBINQ-MIAUTHJWSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 408.88 | Molecular Weight (Monoisotopic): 408.1340 | AlogP: 1.84 | #Rotatable Bonds: 6 |
Polar Surface Area: 99.38 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.57 | CX Basic pKa: | CX LogP: 2.11 | CX LogD: 2.11 |
Aromatic Rings: 2 | Heavy Atoms: 28 | QED Weighted: 0.58 | Np Likeness Score: 0.61 |
1. Xu G, Lv B, Roberge JY, Xu B, Du J, Dong J, Chen Y, Peng K, Zhang L, Tang X, Feng Y, Xu M, Fu W, Zhang W, Zhu L, Deng Z, Sheng Z, Welihinda A, Sun X.. (2014) Design, synthesis, and biological evaluation of deuterated C-aryl glycoside as a potent and long-acting renal sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes., 57 (4): [PMID:24456245] [10.1021/jm401780b] |
Source(1):